Publicaciones en las que colabora con MANUEL GUZMÁN PASTOR (14)

2021

  1. Bip heterozigosity aggravates pathological deterioration in experimental amyotrophic lateral sclerosis

    International Journal of Molecular Sciences, Vol. 22, Núm. 22

2020

  1. Possible therapeutic applications of cannabis in the neuropsychopharmacology field

    European Neuropsychopharmacology, Vol. 36, pp. 217-234

2016

  1. A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington’s disease

    Journal of Neurology, Vol. 263, Núm. 7, pp. 1390-1400

2014

  1. A restricted population of CB1 cannabinoid receptors with neuroprotective activity

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 111, Núm. 22, pp. 8257-8262

  2. Targeting CB2-GPR55 receptor heteromers modulates cancer cell signaling

    Journal of Biological Chemistry, Vol. 289, Núm. 32, pp. 21960-21972

2013

  1. Natural cannabinoids improve dopamine neurotransmission and tau and amyloid pathology in a mouse model of tauopathy

    Journal of Alzheimer's Disease, Vol. 35, Núm. 3, pp. 525-539

2011

  1. Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease

    Brain, Vol. 134, Núm. 1, pp. 119-136

  2. Prospects for cannabinoid therapies in basal ganglia disorders

    British Journal of Pharmacology, Vol. 163, Núm. 7, pp. 1365-1378

  3. Reply: Reliability of immunolabelling in the determination of Huntington's disease neuropathy

    Brain

2009

  1. Actualización sobre el potencial terapéutico de los cannabinoides

    Sociedad Española de Investigación en Cannabinoides (SEIC)

  2. Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity

    Brain, Vol. 132, Núm. 11, pp. 3152-3164

2007

  1. Cannabinoid CB2 receptor: a new target for controlling neural cell survival?

    Trends in Pharmacological Sciences, Vol. 28, Núm. 1, pp. 39-45

  2. Preface: Cannabinoids as new tools for the treatment of neurological disorders

    Molecular Neurobiology

1995

  1. Effects of anandamide on hepatic fatty acid metabolism

    Biochemical Pharmacology, Vol. 50, Núm. 6, pp. 885-888